Castle Biosciences, Inc. (NASDAQ: CSTL) Stock Competitors & Peer Comparison
See CSTL's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CSTL and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CSTL | $34.88 | -2.92% | 1.1B | -52.85 | -$0.66 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.64% |
| TMO | $679.61 | +0.15% | 251.3B | 29.34 | $23.16 | +0.27% |
| DHR | $226.11 | -0.54% | 159B | 28.35 | $7.98 | +0.64% |
| NTRA | $414.52 | +0.67% | 59.4B | -314.03 | -$1.32 | N/A |
| A | $175.03 | -0.10% | 49.4B | 30.12 | $5.81 | +0.58% |
| IQV | $268.99 | -0.73% | 44.3B | 22.19 | $12.13 | N/A |
| WAT | $443.26 | +0.07% | 43.5B | 32.42 | $13.68 | N/A |
| IDXX | $533.44 | +0.83% | 42.1B | 37.51 | $14.22 | N/A |
| ILMN | $272.00 | +0.04% | 41.2B | 54.08 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
CSTL vs DHR-PB Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, CSTL's ROE is -0.04%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, CSTL is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
CSTL vs TMO Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, TMO has a market cap of 251.3B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while TMO trades at $679.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas TMO's P/E ratio is 29.34. In terms of profitability, CSTL's ROE is -0.04%, compared to TMO's ROE of +0.13%. Regarding short-term risk, CSTL is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
CSTL vs DHR Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, DHR has a market cap of 159B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while DHR trades at $226.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas DHR's P/E ratio is 28.35. In terms of profitability, CSTL's ROE is -0.04%, compared to DHR's ROE of +0.08%. Regarding short-term risk, CSTL is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
CSTL vs NTRA Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, NTRA has a market cap of 59.4B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while NTRA trades at $414.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas NTRA's P/E ratio is -314.03. In terms of profitability, CSTL's ROE is -0.04%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, CSTL is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
CSTL vs A Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, A has a market cap of 49.4B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while A trades at $175.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas A's P/E ratio is 30.12. In terms of profitability, CSTL's ROE is -0.04%, compared to A's ROE of +0.20%. Regarding short-term risk, CSTL is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
CSTL vs IQV Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, IQV has a market cap of 44.3B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while IQV trades at $268.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas IQV's P/E ratio is 22.19. In terms of profitability, CSTL's ROE is -0.04%, compared to IQV's ROE of +0.22%. Regarding short-term risk, CSTL is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check IQV's competition here
Waters Corporation (NYSE: WAT)
CSTL vs WAT Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, WAT has a market cap of 43.5B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while WAT trades at $443.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas WAT's P/E ratio is 32.42. In terms of profitability, CSTL's ROE is -0.04%, compared to WAT's ROE of +0.02%. Regarding short-term risk, CSTL is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check WAT's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
CSTL vs IDXX Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, IDXX has a market cap of 42.1B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while IDXX trades at $533.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas IDXX's P/E ratio is 37.51. In terms of profitability, CSTL's ROE is -0.04%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, CSTL is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
CSTL vs ILMN Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, ILMN has a market cap of 41.2B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while ILMN trades at $272.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas ILMN's P/E ratio is 54.08. In terms of profitability, CSTL's ROE is -0.04%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, CSTL is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
CSTL vs MTD Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, MTD has a market cap of 31.1B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while MTD trades at $1,537.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas MTD's P/E ratio is 35.36. In terms of profitability, CSTL's ROE is -0.04%, compared to MTD's ROE of -12.00%. Regarding short-term risk, CSTL is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
CSTL vs DGX Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, DGX has a market cap of 25.6B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while DGX trades at $231.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas DGX's P/E ratio is 22.87. In terms of profitability, CSTL's ROE is -0.04%, compared to DGX's ROE of +0.14%. Regarding short-term risk, CSTL is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
CSTL vs LH Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, LH has a market cap of 25.3B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while LH trades at $308.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas LH's P/E ratio is 18.33. In terms of profitability, CSTL's ROE is -0.04%, compared to LH's ROE of +0.12%. Regarding short-term risk, CSTL is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
CSTL vs GH Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, GH has a market cap of 23.9B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while GH trades at $177.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas GH's P/E ratio is -50.93. In terms of profitability, CSTL's ROE is -0.04%, compared to GH's ROE of +2.11%. Regarding short-term risk, CSTL is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
CSTL vs EXAS Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas EXAS's P/E ratio is -95.37. In terms of profitability, CSTL's ROE is -0.04%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, CSTL is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
CSTL vs MEDP Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, MEDP has a market cap of 17.4B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while MEDP trades at $622.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas MEDP's P/E ratio is 36.47. In terms of profitability, CSTL's ROE is -0.04%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, CSTL is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
CSTL vs RVTY Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, RVTY has a market cap of 17B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while RVTY trades at $152.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas RVTY's P/E ratio is 28.55. In terms of profitability, CSTL's ROE is -0.04%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, CSTL is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
CSTL vs ILMNV Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas ILMNV's P/E ratio is N/A. In terms of profitability, CSTL's ROE is -0.04%, compared to ILMNV's ROE of N/A. Regarding short-term risk, CSTL is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check ILMNV's competition here
PerkinElmer, Inc. (NYSE: PKI)
CSTL vs PKI Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas PKI's P/E ratio is 41.45. In terms of profitability, CSTL's ROE is -0.04%, compared to PKI's ROE of +0.03%. Regarding short-term risk, CSTL is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
CSTL vs CRL Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, CRL has a market cap of 14.3B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while CRL trades at $295.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas CRL's P/E ratio is 29.91. In terms of profitability, CSTL's ROE is -0.04%, compared to CRL's ROE of -0.08%. Regarding short-term risk, CSTL is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
CSTL vs ICLR Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, ICLR has a market cap of 13B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while ICLR trades at $170.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas ICLR's P/E ratio is 13.89. In terms of profitability, CSTL's ROE is -0.04%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, CSTL is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
CSTL vs QGEN Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, QGEN has a market cap of 9.2B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while QGEN trades at $44.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas QGEN's P/E ratio is 18.34. In terms of profitability, CSTL's ROE is -0.04%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, CSTL is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
CSTL vs GRAL Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, GRAL has a market cap of 5.9B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while GRAL trades at $136.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas GRAL's P/E ratio is -14.01. In terms of profitability, CSTL's ROE is -0.04%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, CSTL is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
CSTL vs RDNT Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, RDNT has a market cap of 5.6B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while RDNT trades at $70.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas RDNT's P/E ratio is 153.59. In terms of profitability, CSTL's ROE is -0.04%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, CSTL is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check RDNT's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
CSTL vs BLLN Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, BLLN has a market cap of 5.4B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while BLLN trades at $118.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas BLLN's P/E ratio is 168.83. In terms of profitability, CSTL's ROE is -0.04%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, CSTL is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
CSTL vs SHC Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, SHC has a market cap of 5.3B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while SHC trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas SHC's P/E ratio is 19.38. In terms of profitability, CSTL's ROE is -0.04%, compared to SHC's ROE of +0.27%. Regarding short-term risk, CSTL is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
CSTL vs SYNH Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas SYNH's P/E ratio is 61.40. In terms of profitability, CSTL's ROE is -0.04%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, CSTL is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
CSTL vs VCYT Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, VCYT has a market cap of 3.7B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while VCYT trades at $46.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas VCYT's P/E ratio is 23.04. In terms of profitability, CSTL's ROE is -0.04%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, CSTL is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
CSTL vs CDNA Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while CDNA trades at $64.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas CDNA's P/E ratio is 76.21. In terms of profitability, CSTL's ROE is -0.04%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, CSTL is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
CSTL vs OLK Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas OLK's P/E ratio is -96.59. In terms of profitability, CSTL's ROE is -0.04%, compared to OLK's ROE of -0.07%. Regarding short-term risk, CSTL is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
CSTL vs WGS Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, WGS has a market cap of 2.3B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while WGS trades at $75.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas WGS's P/E ratio is 210.53. In terms of profitability, CSTL's ROE is -0.04%, compared to WGS's ROE of -0.39%. Regarding short-term risk, CSTL is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
CSTL vs PSNL Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while PSNL trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas PSNL's P/E ratio is -15.00. In terms of profitability, CSTL's ROE is -0.04%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, CSTL is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
CSTL vs OPK Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while OPK trades at $1.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas OPK's P/E ratio is -6.00. In terms of profitability, CSTL's ROE is -0.04%, compared to OPK's ROE of -0.06%. Regarding short-term risk, CSTL is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check OPK's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
CSTL vs FLGT Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, FLGT has a market cap of 627.1M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while FLGT trades at $22.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas FLGT's P/E ratio is 2208.00. In terms of profitability, CSTL's ROE is -0.04%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, CSTL is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
CSTL vs GRALV Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas GRALV's P/E ratio is N/A. In terms of profitability, CSTL's ROE is -0.04%, compared to GRALV's ROE of N/A. Regarding short-term risk, CSTL is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
CSTL vs NEO Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, NEO has a market cap of 481.5M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while NEO trades at $18.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas NEO's P/E ratio is 144.15. In terms of profitability, CSTL's ROE is -0.04%, compared to NEO's ROE of -0.06%. Regarding short-term risk, CSTL is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
CSTL vs CO Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas CO's P/E ratio is 5.06. In terms of profitability, CSTL's ROE is -0.04%, compared to CO's ROE of +0.11%. Regarding short-term risk, CSTL is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
CSTL vs MYGN Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, MYGN has a market cap of 399.5M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while MYGN trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas MYGN's P/E ratio is -32.54. In terms of profitability, CSTL's ROE is -0.04%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, CSTL is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
CSTL vs FLDM Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas FLDM's P/E ratio is -4.74. In terms of profitability, CSTL's ROE is -0.04%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, CSTL is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
CSTL vs BDSX Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, BDSX has a market cap of 237.2M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while BDSX trades at $29.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas BDSX's P/E ratio is -9.19. In terms of profitability, CSTL's ROE is -0.04%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, CSTL is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
CSTL vs XGN Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, XGN has a market cap of 204.9M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while XGN trades at $8.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas XGN's P/E ratio is -10.47. In terms of profitability, CSTL's ROE is -0.04%, compared to XGN's ROE of -1.22%. Regarding short-term risk, CSTL is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
CSTL vs FRNM Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, FRNM has a market cap of 129.9M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while FRNM trades at $15.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas FRNM's P/E ratio is N/A. In terms of profitability, CSTL's ROE is -0.04%, compared to FRNM's ROE of N/A. Regarding short-term risk, CSTL is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
CSTL vs GTH Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas GTH's P/E ratio is -1.11. In terms of profitability, CSTL's ROE is -0.04%, compared to GTH's ROE of -1.01%. Regarding short-term risk, CSTL is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
CSTL vs GENE Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas GENE's P/E ratio is -38.25. In terms of profitability, CSTL's ROE is -0.04%, compared to GENE's ROE of -1.85%. Regarding short-term risk, CSTL is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
CSTL vs IMDX Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, IMDX has a market cap of 109.1M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while IMDX trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas IMDX's P/E ratio is -2.27. In terms of profitability, CSTL's ROE is -0.04%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, CSTL is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
CSTL vs SERA Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, SERA has a market cap of 78.3M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while SERA trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas SERA's P/E ratio is -3.15. In terms of profitability, CSTL's ROE is -0.04%, compared to SERA's ROE of -0.47%. Regarding short-term risk, CSTL is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
CSTL vs PRPO Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, PRPO has a market cap of 42.1M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while PRPO trades at $23.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas PRPO's P/E ratio is -36.28. In terms of profitability, CSTL's ROE is -0.04%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, CSTL is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
CSTL vs QUCY Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, QUCY has a market cap of 29.4M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while QUCY trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas QUCY's P/E ratio is -0.06. In terms of profitability, CSTL's ROE is -0.04%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, CSTL is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
CSTL vs MDXH Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, MDXH has a market cap of 26.7M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while MDXH trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas MDXH's P/E ratio is -0.71. In terms of profitability, CSTL's ROE is -0.04%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, CSTL is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
CSTL vs AKU Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas AKU's P/E ratio is -0.13. In terms of profitability, CSTL's ROE is -0.04%, compared to AKU's ROE of -5.32%. Regarding short-term risk, CSTL is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
CSTL vs BNR Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, BNR has a market cap of 20M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while BNR trades at $18.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas BNR's P/E ratio is -21.77. In terms of profitability, CSTL's ROE is -0.04%, compared to BNR's ROE of -0.13%. Regarding short-term risk, CSTL is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
CSTL vs CEMI Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas CEMI's P/E ratio is -0.63. In terms of profitability, CSTL's ROE is -0.04%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, CSTL is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
CSTL vs ENZ Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas ENZ's P/E ratio is -2.24. In terms of profitability, CSTL's ROE is -0.04%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, CSTL is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
CSTL vs PMD Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas PMD's P/E ratio is -5.24. In terms of profitability, CSTL's ROE is -0.04%, compared to PMD's ROE of -0.32%. Regarding short-term risk, CSTL is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
CSTL vs ME Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas ME's P/E ratio is -0.03. In terms of profitability, CSTL's ROE is -0.04%, compared to ME's ROE of -42.03%. Regarding short-term risk, CSTL is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
CSTL vs MYNZ Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, CSTL's ROE is -0.04%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, CSTL is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check MYNZ's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
CSTL vs BIAFW Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, BIAFW has a market cap of 11.4M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while BIAFW trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas BIAFW's P/E ratio is 1.21. In terms of profitability, CSTL's ROE is -0.04%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, CSTL is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check BIAFW's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
CSTL vs CHEK Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas CHEK's P/E ratio is -0.43. In terms of profitability, CSTL's ROE is -0.04%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, CSTL is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
CSTL vs CNTG Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas CNTG's P/E ratio is -0.23. In terms of profitability, CSTL's ROE is -0.04%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, CSTL is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
CSTL vs ADVB Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, ADVB has a market cap of 8.7M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while ADVB trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas ADVB's P/E ratio is -57.45. In terms of profitability, CSTL's ROE is -0.04%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, CSTL is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
CSTL vs NDRA Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, NDRA has a market cap of 7.5M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while NDRA trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas NDRA's P/E ratio is -0.88. In terms of profitability, CSTL's ROE is -0.04%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, CSTL is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
CSTL vs APDN Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas APDN's P/E ratio is -0.10. In terms of profitability, CSTL's ROE is -0.04%, compared to APDN's ROE of -7.23%. Regarding short-term risk, CSTL is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
CSTL vs NVTA Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas NVTA's P/E ratio is -0.00. In terms of profitability, CSTL's ROE is -0.04%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, CSTL is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
CSTL vs LMDX Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas LMDX's P/E ratio is -0.01. In terms of profitability, CSTL's ROE is -0.04%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, CSTL is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
CSTL vs LMDXW Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, CSTL's ROE is -0.04%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, CSTL is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check LMDXW's competition here
DermTech, Inc. (NASDAQ: DMTK)
CSTL vs DMTK Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas DMTK's P/E ratio is -0.04. In terms of profitability, CSTL's ROE is -0.04%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, CSTL is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check DMTK's competition here
iSpecimen Inc. (NASDAQ: ISPC)
CSTL vs ISPC Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, ISPC has a market cap of 3M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while ISPC trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas ISPC's P/E ratio is -0.04. In terms of profitability, CSTL's ROE is -0.04%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, CSTL is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check ISPC's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
CSTL vs BIAF Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, BIAF has a market cap of 2.9M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while BIAF trades at $6.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas BIAF's P/E ratio is -0.81. In terms of profitability, CSTL's ROE is -0.04%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, CSTL is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check BIAF's competition here
Inotiv, Inc. (NASDAQ: NOTV)
CSTL vs NOTV Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas NOTV's P/E ratio is -0.03. In terms of profitability, CSTL's ROE is -0.04%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, CSTL is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
CSTL vs SQL Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas SQL's P/E ratio is -0.40. In terms of profitability, CSTL's ROE is -0.04%, compared to SQL's ROE of -30.46%. Regarding short-term risk, CSTL is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
CSTL vs AWH Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas AWH's P/E ratio is -0.09. In terms of profitability, CSTL's ROE is -0.04%, compared to AWH's ROE of +1.62%. Regarding short-term risk, CSTL is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
CSTL vs HTGM Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas HTGM's P/E ratio is -0.03. In terms of profitability, CSTL's ROE is -0.04%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, CSTL is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
CSTL vs BIOC Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas BIOC's P/E ratio is -0.01. In terms of profitability, CSTL's ROE is -0.04%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, CSTL is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
CSTL vs SQLLW Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, CSTL's ROE is -0.04%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, CSTL is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
CSTL vs WGSWW Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, CSTL's ROE is -0.04%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, CSTL is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check WGSWW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
CSTL vs OCDX Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas OCDX's P/E ratio is -42.28. In terms of profitability, CSTL's ROE is -0.04%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, CSTL is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check OCDX's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
CSTL vs MEUSW Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas MEUSW's P/E ratio is N/A. In terms of profitability, CSTL's ROE is -0.04%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, CSTL is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check MEUSW's competition here
Danaher Corporation (NYSE: DHR-PA)
CSTL vs DHR-PA Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, CSTL's ROE is -0.04%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, CSTL is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check DHR-PA's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
CSTL vs NDRAW Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas NDRAW's P/E ratio is N/A. In terms of profitability, CSTL's ROE is -0.04%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, CSTL is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check NDRAW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
CSTL vs BNGOW Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas BNGOW's P/E ratio is N/A. In terms of profitability, CSTL's ROE is -0.04%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, CSTL is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check BNGOW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
CSTL vs CHEKZ Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, CSTL's ROE is -0.04%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, CSTL is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check CHEKZ's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
CSTL vs PRXL Comparison September 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1.1B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, CSTL is priced at $34.88 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -52.85, whereas PRXL's P/E ratio is 42.97. In terms of profitability, CSTL's ROE is -0.04%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, CSTL is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check PRXL's competition here